These results support that manipulations of TGF 1 or therapies to target SMAD3 may be potential therapeutic targets to treat ALF patients who have the potential to develop HE
Cytoplasmic mitochondrial precursor proteins are protected and unfolded by chaperone proteins such as Hsp90 in the cytoplasm before entering mitochondria
Complications of carnitine deficiency include: Heart problems: One very dangerous potential consequence is heart weakening
Measurement of GSH and GSSG in RBCs with HPLC-BDD To determine the amount of GSH and GSSG in RBCs, HPLC (ESA Coularray) with electrochemical detection (ECD) was used following the protocol outlined by Park et al
P., Busija, L., & Downie, L
Pre-Blend Weekly Schedule Example Pre-blend dose at each titration step Phase Start Weeks 1-4 Draw Volume 0.40 mL (40 units) Reta Delivered 2.0 mg Cag Delivered 0.4 mg Phase Step 1 Weeks 5-8 Draw Volume 0.60 mL (60 units) Reta Delivered 3.0 mg Cag Delivered 0.6 mg Phase Step 2 Weeks 9-16 Draw Volume 0.80 mL (80 units) Reta Delivered 4.0 mg Cag Delivered 0.8 mg Phase Step 3 Weeks 17-20 Draw Volume 1.20 mL (120 units) Reta Delivered 6.0 mg Cag Delivered 1.2 mg Phase Step 4 Weeks 21-24 Draw Volume 1.60 mL (160 units) Reta Delivered 8.0 mg Cag Delivered 1.6 mg Phase Maintenance Weeks 25+ Draw Volume 2.40 mL (240 units) Reta Delivered 12.0 mg Cag Delivered 2.4 mg One injection per week
